Immatics at the 15th Annual Personalized Medicine Conference (Nov 13-14) in Boston, MA

| News, USA

The Paradigm Evolvers

The Personalized Medicine Coalition (PMC) will host its 15th annual conference on November 13-14, 2019 at the Harvard Medical School in Boston, MA. Meet CEO Harpreet Singh and put current pipelines to the test: Join him, CNBC reporter Meg Tirrell and his fellow panelists in exploring the implications of a biopharmaceutical pipeline dominated by personalized treatments.

 

Thursday, Nov 14, 10.45am – 11.45am │ Joseph B. Martin Conference Center

Day 2: Targeting Treatment  

Panel: Prospecting the Pipeline: Exploring the Implications of a Biopharmaceutical Pipeline Dominated by Personalized Treatments

Panelist: Harpreet Singh, CEO Immatics

As researchers develop an enhanced understanding of the molecular causes that underpin various diseases, many biopharmaceutical companies have begun to develop therapies that are targeted to patient subgroups and even personalized to individual patients. In oncology, for example, there are reportedly more than 900 personalized “immunotherapy” treatments being tested in the clinic, with more than 1,000 in preclinical development. The challenging scientific questions and systemic implications associated with these new therapies do not always fit neatly into existing regulatory, payment, and care delivery frameworks.

During this session, CNBC Reporter Ms. Meg Tirrell will moderate a panel discussion that explores the scientific, regulatory, reimbursement, and other systemic issues associated with future gene editing treatments, gene therapies, immunotherapies, and targeted therapies. The panelists, who include industry representatives, a researcher, and an academic leader, will also consider a new approach to immunotherapy for cancer patients in which a unique product is developed for every patient treated.

  

Further information on the PMC conference 2019 can be found here.

Press Contact

Anja Heuer

Corporate Communications,
Immatics Biotechnologies GmbH

+49 89 540 415 606

Go back

We use cookies to ensure that we give you the best experience on our website.